DAN IOANITESCU: Open Payments
NPI 1720024292 · WARNER ROBINS, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,131 in 55 payments from 16 companies in 2025. Trend: 2023 $659 · 2024 $1,013 · 2025 $1,131
Food & beverage: $1,131
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 7 | $209 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $189 |
| Otsuka America Pharmaceutical, Inc. | 8 | $143 |
| Alkermes, Inc. | 4 | $96 |
| Vanda Pharmaceuticals Inc. | 5 | $94 |
| ABBVIE INC. | 3 | $71 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Noven Therapeutics, LLC | 2 | $41 |
Products named: INGREZZA, CAPLYTA, REXULTI, ARISTADA, FANAPT, VRAYLAR, COBENFY, Auvelity.
Industry payments across GA — which companies pay providers there.
